Evidence map›Paper›PMID 42932090›Full record

ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026

Snake venom toxins in cancer therapy: advances in targeted delivery and peptide design.

Akmal M Asrorov, Matluba Mirzaeva, Muzaffar Kayumov, Shamsiddin Fazliddinov, Khamza S Toshov, Okhunjon Khasanov, Gulnora Rakhmonova, Ahmidin Wali, Hayotbek A Abdullaev, Nurkhodja Mukhamedov

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Akmal M AsrorovInstitute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, 83, M. Ulughbek Street, 100125, Tashkent, Uzbekistan. akmal84a@gmail.com.ORCID http://orcid.org/0000-0001-5700-1061
Matluba MirzaevaTashkent State Medical University, 2, Farabiy Street, 100109, Tashkent, Uzbekistan.
Muzaffar KayumovInstitute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, 83, M. Ulughbek Street, 100125, Tashkent, Uzbekistan.
Shamsiddin FazliddinovInstitute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, 83, M. Ulughbek Street, 100125, Tashkent, Uzbekistan.
Khamza S ToshovNational University of Uzbekistan, 4, Universitet Street, 100174, Tashkent, Uzbekistan.
Okhunjon KhasanovKimyo International University, 156, Rustaveli Street, 100121, Tashkent, Uzbekistan.
Gulnora RakhmonovaInstitute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, 83, M. Ulughbek Street, 100125, Tashkent, Uzbekistan.
Ahmidin WaliXinjiang Technical Institute of Physics and Chemistry, 40-1 Beijing Road, 830011, Urumqi, China.
Hayotbek A AbdullaevNational Biopharmaceutical Research Institute, Tashkent BioPharmaCity, 1 Bogzor Street, Tashkent, Uzbekistan.
Nurkhodja MukhamedovInstitute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, 83, M. Ulughbek Street, 100125, Tashkent, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Snake venom represents a potent biological arsenal of cytotoxic compounds. Venom proteins and peptides, including disintegrins, venomous enzymes, three-finger toxins, and serine proteases, have garnered attention as effective anticancer agents. Despite their efficacy at nano- or micromolar concentrations, non-standardized mixtures often limit their therapeutic utilization, necessitating fractionation to minimize side effects. This review examines the antitumor potential of snake venom and its constituent proteins and peptides through a literature search in NCBI PubMed. We highlight the antitumor efficacies of venom polypeptides by correlating them with IC

Indexed as

Cancer therapyCilengitideDelivery systemsDisintegrinPeptidesSnake venom

Identifiers

PMID42932090
PMCPMC13710528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.